-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TTI-621 (SIRPα-IgG1 Fc) is a unique SIRPαFc decoy receptor that can target CD47 and block its activity
A multicenter, open-label Phase 1 study conducted at 5 academic medical and research centers in the United States evaluated the use of TTI-621 in percutaneously treatable relapsed or refractory mycosis fungoides (a type of T cell Safety and activity in patients with malignant tumors of origin), Sézary syndrome or solid tumors
Schematic diagram of TTI-621
Schematic diagram of TTI-621Recruited patients who were over 18 years of age with injectable, histologically or cytologically confirmed relapsed or refractory cutaneous T-cell lymphoma (CTCL) or solid tumors
Lymphoma
From January 30, 2017 to March 31, 2020, a total of 66 patients were screened , of which 35 patients with mycosis fungoides or Sézary syndrome were recruited into the group and received intratumoral injection of TTI-621 (incremental Dose cohort: n=13; extended group, n=22)
No dose-limiting toxicity occurred during
The mechanism of CD47 anti-tumor activity mediated by TTI-621
The mechanism of CD47 anti-tumor activity mediated by TTI-621Treatment-related adverse events occurred in 25 (71%) patients; the most common (≥10% of patients) adverse events were chills (29%), injection site pain (26%), and fatigue (23%)
Treatment-related adverse events occurred in 25 (71%) patients; the most common (≥10% of patients) adverse events were chills (29%), injection site pain (26%), and fatigue (23%)
Ten patients (34%) had a decrease in CAILS score of ≥50% (CAILS remission)
For patients with relapsed or refractory mycosis fungoides or Sézary syndrome, intratumoral injection of TTI-621 is well tolerated, and anti-tumor activity is detected in adjacent or distant non-injected lesions, suggesting TTI-621 It has systemic and local remote effects, and has the potential as an immunotherapy for these diseases.
Original source:
Christiane Querfeld, et al.
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
in this message
